Ayisha SharmaNews ReporterKatherine LewinNews ReporterNovo Nordisk and Eli Lilly are set to make billions of dollars each year off their GLP-1s, but patients and prescribers are still eager for improved drugs, citing GI side effects, muscle loss and weight gain after stopping treatment Add in the potential for drugs like Novo’s semaglutide (marketed as Wegovy...